Fennec Pharmaceuticals (FENC) H.C. Wainwright 26th Annual Global Investment Conference 2024 summary

Conference overview

• H.C. Wainwright hosted its 26th Annual Global Investment Conference, providing a platform for corporate finance and strategic advisory discussions across sectors.

• Fennec Pharmaceuticals presented, focusing on their commercial-stage operations and product developments.

Product and clinical highlights

• Pedmark, a unique sodium thiosulfate formulation, is FDA and EMA approved for preventing cisplatin-induced hearing loss in pediatric patients.

• Launched in October 2022, Pedmark demonstrated a 50% reduction in hearing loss in two phase III trials.

• The product addresses a significant unmet need, as prior to its approval, no interventions existed to prevent irreversible hearing loss from cisplatin.

• Pedmark is the only approved treatment for this indication, with no branded competitors in development.

Commercial strategy and partnerships

• Entered a licensing agreement with Norgine in March 2024 for commercialization in Europe, Australia, and New Zealand, with $43 million upfront and up to $230 million in milestones.

• Holds 10 years of exclusivity in Europe and seven years in the U.S. through regulatory protections.

• Commercial strategy includes education, awareness, and partnerships with advocacy groups and key opinion leaders.

• Fennec HEARS program supports patient access and insurance navigation.